Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Publication date: Apr 22, 2022

This phase I trial finds out the side effects and possible benefits of stereotactic radiosurgery and immune checkpoint inhibitors with NovoTTF-100M for the treating of melanoma that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. It is used to treat brain tumors and other brain disorders that cannot be treated by regular surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. NovoTTF-100M is a portable battery operated device which produces tumor treating fields in the body by means of surface electrodes placed on the skin. Tumor treating fields are low intensity, intermediate frequency electric fields that pulse through the skin to disrupt cancer cells’ ability to divide. Giving stereotactic radiosurgery and immune checkpoint inhibitors with NovoTTF-100M may work better than stereotactic radiosurgery and immune checkpoint inhibitors.

Concepts Keywords
100m Enrollment protocol
Cancer CMP
Childbearing Chemotherapy
Inactivated Neurosurgery
Neurosurgery MRI
Radiation
Antibodies
Radiation therapy
Stereotactic surgery
Brain metastasis
Radiosurgery
Radiobiology
Cancer treatments
Neurosurgery
Antineoplastic drugs
Cancer immunotherapy
Health sciences
Clinical medicine
Enrollment protocol

Semantics

Type Source Name
disease MESH papilledema
disease MESH influenza
pathway KEGG Hepatitis C
disease MESH hepatitis C
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
pathway KEGG Hepatitis B
disease MESH hepatitis B
disease MESH substance abuse
disease MESH infection
disease MESH pneumonitis
disease MESH pituitary insufficiency
disease MESH autoimmune disease
disease MESH cervical cancer
pathway KEGG Basal cell carcinoma
disease MESH basal cell carcinoma
disease MESH complications
disease MESH Hypersensitivity
drug DRUGBANK Aspartame
disease MESH life style
drug DRUGBANK Prothrombin
disease MESH metastases
drug DRUGBANK L-Alanine
drug DRUGBANK Creatinine
drug DRUGBANK Erythropoietin
drug DRUGBANK Cytidine-5′-Monophosphate
disease MESH biopsy
drug DRUGBANK Dexamethasone
drug DRUGBANK Prednisone
disease MESH disease progression
disease MESH diagnosis
drug DRUGBANK Tropicamide
pathway REACTOME Immune System
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
drug DRUGBANK Pembrolizumab
disease MESH brain disorders
disease MESH tumor
disease MESH Brain Metastases
pathway KEGG Melanoma
disease MESH Melanoma

Original Article

Leave a Comment

Your email address will not be published.